Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT04503278

A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors

Led by BioNTech Cell & Gene Therapies GmbH · Updated on 2026-04-17

214

Participants Needed

12

Research Sites

1089 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a Phase I, FIH, open-label, multi-site, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of claudin 6 (CLDN6) chimeric antigen receptor T cells (CAR-T) with or without CLDN6 ribonucleic acid lipoplexes (RNA-LPX) in patients with CLDN6-positive relapsed or refractory advanced solid tumors.

CONDITIONS

Official Title

A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Must have a tumor that is at least 50% CLDN6-positive as confirmed by a central lab test
  • Must provide a recent tumor tissue sample no older than 3 years for testing
  • Must have a confirmed solid tumor that is metastatic or cannot be removed by surgery
  • Must have measurable disease by standard criteria or tumor markers
  • Must be 18 years of age or older at time of consent
  • Must be willing and able to sign informed consent and participate in trial procedures
  • Must have good overall health status with performance score 0 to 1
  • Must have adequate blood, liver, kidney, and clotting function as defined by the study
  • Women of childbearing potential must have a negative pregnancy test and agree to use effective birth control
  • Men and women must agree to avoid fathering or becoming pregnant during the study and for 12 months after treatment
  • Must be able to attend all required trial visits
Not Eligible

You will not qualify if you...

  • Previous CAR-T therapy other than CLDN6 CAR-T
  • Vaccination with live virus within 6 weeks before starting treatment
  • Use of systemic steroids over 10 mg prednisolone daily
  • Unresolved side effects from prior treatments at grade 1 or higher
  • New or growing brain or spinal metastases unless stable and treated as specified
  • History of epilepsy or recent cerebrovascular event within 6 months
  • Pericardial effusion requiring drainage
  • Active autoimmune disease requiring immunosuppressive treatment (with some exceptions)
  • HIV infection
  • Active hepatitis B or C infection requiring treatment
  • Known allergy to study drugs or similar compounds
  • Severe reaction history to study chemotherapy drugs
  • Other primary cancers within past 2 years (exceptions apply)
  • Prior allogeneic stem cell transplant within 5 years
  • Acute or chronic graft versus host disease
  • Significant heart, lung, or other medical conditions posing safety risk
  • Cognitive or psychological issues preventing trial compliance
  • Pregnant or breastfeeding
  • Pure beta-hCG-secreting germ cell tumor

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 12 locations

1

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia, 3000

Completed

2

Charité - Universitätsmedizin Berlin - Campus Benjamin Franklin

Berlin, Germany, 12200

Actively Recruiting

3

Universitätsklinikum Köln AÖR-Centrum für Integrierte Onkologie (CIO)-Studienzentrum der Klinik I für Innere Medizin (CTU Cologne)

Cologne, Germany, 50937

Actively Recruiting

4

Universitätsklinikum Erlangen - Hämatologie & Intrinsische Onkologie - Medizinische Klinik 5

Erlangen, Germany, 91054

Actively Recruiting

5

Universitätsklinikum Hamburg Eppendorf - II Medizinische Klinik und Poliklinik

Hamburg, Germany, 20246

Actively Recruiting

6

Medizinische Hochschule Hannover - Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation

Hanover, Germany, 30625

Actively Recruiting

7

Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg

Heidelberg, Germany, 69120

Actively Recruiting

8

Universitätsmedizin Mainz - III Medizinische Klinik und Poliklinik

Mainz, Germany, 55131

Actively Recruiting

9

Universitätsklinikum Regensburg - Klinik und Poliklinik für Innere Medizin III

Regensburg, Germany, 93053

Actively Recruiting

10

He Nederlands Kanker Instituut (The Netherlands Cancer Institute) - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)

Amsterdam, Netherlands, 1066

Actively Recruiting

11

Erasmus MC - Universitair Medisch Centrum - Medical oncology

Rotterdam, Netherlands, 3015

Actively Recruiting

12

Karolinska Comprehensive Cancer Center Cancerstudieenheten Huddinge Karolinska Universitetssjukhuset

Stockholm, Sweden, 14186

Actively Recruiting

Loading map...

Research Team

B

BioNTech clinical trials patient information

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

FACTORIAL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors | DecenTrialz